Latest News
Conference Coverage
Tofacitinib and TNF inhibitors show similar VTE rates
A review of more than 50,000 U.S. rheumatoid arthritis patients shows similar venous thromboembolism rates with tofacitinib and TNF inhibition.
Conference Coverage
Nasal glucagon ‘viable alternative’ to intramuscular administration
BERLIN – Severe hypoglycemia was reversed successfully in all patients with type 1 diabetes mellitus given nasal glucagon.
From the Journals
All patients with VTE have a high risk of recurrence
Researchers suggest rethinking categorization of patients with incident venous thromboembolism.
Conference Coverage
Novel topical JAK inhibitor shows promise for atopic dermatitis
PARIS – Ruxolitinib may offer a desperately needed alternative to potent topical steroids.
Video
‘Phenomenal’ REDUCE-IT establishes triglyceride theory
Why did REDUCE-IT succeed while other trials and compounds failed? Dr. Deedwania explains that it, for the first time, used the appropriate...
From the Journals
ADA releases guidelines for type 2 diabetes in children, youth
Once a diagnosis is made, treatment includes lifestyle management and pharmacologic therapy.
FDA/CDC
FDA approves rifamycin for treatment of traveler’s diarrhea
Rifamycin wins FDA approval for management of E. coli-related traveler's diarrhea.
Conference Coverage
High incidence of treatment-resistant hypertension in SLE comes with high mortality
CHICAGO – Treatment-resistant hypertension is associated with a 289% increased all-cause mortality risk in systemic lupus erythematosus.
